Skip to main content

Macarena Simon-Talero Horga

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Macarena Simon-Talero Horga

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Investigación traslacional en complicaciones de la cirrosis: del modelo experimental a la clínica y viceversa

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Macarena Simon-Talero Horga, Mònica Pons Delgado
Funding agency: Instituto de Salud Carlos III
Funding: 130075
Reference: PI15/00066
Duration: 01/01/2016 - 31/10/2019

Efectos de la administración de albúmina en pacientes cirròticos con encefalopatia hepática

IP: Joan Genescà Ferrer
Collaborators: Meritxell Ventura Cots, Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 242000
Reference: ICI14/00352
Duration: 01/01/2015 - 30/06/2019

Estudio cirrosis hepática

IP: Joan Genescà Ferrer
Collaborators: Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 53732
Reference: CM14/00220
Duration: 06/04/2015 - 05/04/2017

Malalties Hepatobiliars (GRC)

IP: Rafael Esteban Mur
Collaborators: Beatriz Minguez Rosique, Immaculada Raurell Saborit, Lluís Viladomiu Catà, Antonio González Fernández, Lluis Castells Fusté, Maria del Mar Riveiro Barciela, Francisco Rodríguez Frias, Silvia Sauleda Oliveras, Victor Manuel Vargas Blasco, Maria Buti Ferret, Torrens Buscató, Maria Margarita, Josep Quer Sivila, Josep Gregori Font, Maria Nieves Martell Pérez-Alcalde, Damir Garcia Cehic, Juan Ignacio Esteban Mur, Meritxell Ventura Cots, Macarena Simon-Talero Horga, Joan Genescà Ferrer, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 65000
Reference: 2014 SGR 421
Duration: 01/01/2014 - 31/12/2016

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Berta Caralt Ramisa

Berta Caralt Ramisa

Predoctoral researcher
Shock, Organ Dysfunction and Resuscitation
Read more
Laura Ludovica Gramegna .

Laura Ludovica Gramegna .

Predoctoral researcher
Clinical Neuroimmunology
Read more
Francesc Xavier Serra Marin

Francesc Xavier Serra Marin

Research assistant
Biomedical Research in Gynaecology
Read more
Anna Sole Fores

Anna Sole Fores

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.